232 related articles for article (PubMed ID: 18521500)
1. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Gieseler F
Thromb Haemost; 2008 Jun; 99(6):1001-7. PubMed ID: 18521500
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
[TBL] [Abstract][Full Text] [Related]
4. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
5. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
8. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Martin MG; Vij R
Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
[TBL] [Abstract][Full Text] [Related]
10. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
11. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Bladé J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine DL; Anderson KC; Harousseau JL
Br J Haematol; 2008 Oct; 143(2):222-9. PubMed ID: 18713253
[TBL] [Abstract][Full Text] [Related]
13. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide in the treatment of multiple myeloma.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Raje N; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
18. Should we screen patients for inherited thrombophilia before starting thalidomide?
Otrock ZK; Mahfouz RA; El-Hajj II; Harb MI; Sawaya RA
Am J Clin Oncol; 2006 Feb; 29(1):100-1. PubMed ID: 16462512
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
Wiley KE
Clin J Oncol Nurs; 2007 Dec; 11(6):847-51. PubMed ID: 18063543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]